Locus Biosciences Inc., a Research Triangle Park, N.C.-based biotechnology company, closed a $19m Series A funding.
The round was led by Artis Ventures, with participation from Tencent Holdings Limited, Abstract Ventures, and the North Carolina Biotechnology Center, among others.
The company intends to use the funds to file its first IND, as well as to conduct subsequent first-in-human trials.
Founded in 2015 by Paul Garofolo, CEO, Locus Biosciences is a biotechnology company focused on the discovery and development of a CRISPR-Cas platform for precision antimicrobials. The company designs and creates novel CRISPR RNAs (guide RNAs) that direct the Cas3 nuclease to target and kill bacteria cells by irreversibly destroying DNA.